Form 4: Health Catalyst General Counsel Sells Shares Under Pre-Arranged Trading Plan

Health Catalyst's General Counsel, Benjamin Landry, sold 19,268 shares of common stock at a price of $8.3192 per share, totaling $72,250, under a pre-arranged trading plan.

Summary

• Health Catalyst's General Counsel, Benjamin Landry, executed a sale of 19,268 shares of the company's common stock.
• The sale occurred on December 6, 2024.
• The shares were sold at a price of $8.3192 per share.
• The total value of the transaction was $72,250.
• This sale was conducted under a pre-arranged trading plan adopted on March 1, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document reports a routine insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's overall performance.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice for corporate executives to avoid accusations of insider trading.

Comparison to Industry Standards

• Many public companies have executives who use 10b5-1 trading plans to manage their stock sales.
• The sale by Benjamin Landry is similar to other insider sales in the healthcare technology sector.
• The size of the sale is relatively small compared to the overall market capitalization of Health Catalyst.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on investor sentiment, but it is unlikely to significantly affect the company's stock price due to the pre-arranged nature of the sale.

Key Dates

Keywords

Health Catalyst, HCAT, stock sale, insider trading, Rule 10b5-1, Benjamin Landry, General Counsel